#Regemat 3D #VitroInk #TheWell Bioscience

Regemat 3D to Distribute VitroInk® Bioinks: A Strategic Move for Enhanced Bioprinting Solutions

In an exciting development for the bioprinting landscape, REGEMAT 3D, a pioneering company in 3D biofabrication technology, has announced a strategic partnership with TheWell Bioscience. This collaboration will see REGEMAT 3D distribute the innovative VitroInk®, a state-of-the-art bioink specially designed for 3D bioprinting applications.

This partnership aims to combine the advanced bioprinting technologies of REGEMAT 3D with the impressive bioink capabilities of TheWell Bioscience, thereby expanding their product offerings and enhancing the research capabilities available to scientists and clinicians in Europe.

Advancements in Biofabrication

REGEMAT 3D has established itself as a leader in the realm of biofabrication, known for its commitment to developing customizable bioprinters, bioreactors, and biomaterials tailored for use in tissue engineering and regenerative medicine. By incorporating VitroInk® into its product portfolio, the company can now offer a more comprehensive selection of biomaterials to support a diverse range of research initiatives.

VitroInk® stands out due to its unique formulation, which is xeno-free—meaning it does not use animal-derived components. This quality allows cells to be directly mixed with the bioink, bypassing the need for harmful UV curing, heating, or additional crosslinking agents in the 3D printing process. These features ensure optimal conditions for cell growth and differentiation, solidifying VitroInk®'s place as a leading solution for applications in regenerative medicine and tissue engineering.

A Mutual Vision for Innovation

The executives from both companies express enthusiasm over this partnership. Manuel Figueruela, CEO of REGEMAT 3D, emphasized the importance of innovation in bioprinting: “We are committed to advancing the field of bioprinting through innovative technologies. Our collaboration with TheWell Bioscience will empower us to provide cutting-edge bioinks like VitroInk® to significantly enhance our customers' research outcomes.”

On the other hand, John Huang, CEO of TheWell Bioscience, shares a like-minded sentiment, stating, “We are thrilled to partner with REGEMAT 3D, a company that aligns perfectly with our vision for advancing bioprinting. We believe that combining our VitroInk® bioinks with Regemat 3D's advanced bioprinters will equip researchers with the necessary tools to make groundbreaking innovations in tissue engineering.